Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022
Abstract Tick-borne encephalitis (TBE) is an increasing health threat in Sweden and elsewhere in Europe. TBE vaccination is commonly recommended in Sweden, but limited data are available on uptake, effectiveness, and impact of TBE vaccination. General population surveys conducted in 2019–2022 were u...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-86968-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585831855947776 |
|---|---|
| author | Andreas Palmborg Frederick J. Angulo Pingping Zhang Andreas Pilz James Stark Jennifer C. Moïsi Luis Jodar |
| author_facet | Andreas Palmborg Frederick J. Angulo Pingping Zhang Andreas Pilz James Stark Jennifer C. Moïsi Luis Jodar |
| author_sort | Andreas Palmborg |
| collection | DOAJ |
| description | Abstract Tick-borne encephalitis (TBE) is an increasing health threat in Sweden and elsewhere in Europe. TBE vaccination is commonly recommended in Sweden, but limited data are available on uptake, effectiveness, and impact of TBE vaccination. General population surveys conducted in 2019–2022 were used to estimated TBE vaccine uptake. TBE vaccine effectiveness (VE) was estimated using the screening method utilizing the surveys and public health TBE surveillance data, which predominately includes hospitalized TBE cases, from 2018 to 2022. Impact of TBE vaccination was calculated based on disease incidence and observed VE. In 2018–2022, 2,015 TBE cases were reported in Sweden; 82.8% (1,564/1,890) of cases with known TBE vaccination history were unvaccinated. Among persons surveyed from the general population with known vaccination history, 52.0% (11,562/22,247) were unvaccinated. Three dose VE against TBE was 89.0% (95% confidence interval 84.3–92.4). When stratified by age group, VE was 86.0% (55.7–95.6) in 1–15 years-of-age and 93.8% (87.5–96.9) in 16–49 years-of-age. In a conservative estimate, despite suboptimal compliance with TBE vaccination recommendations, vaccination averted an estimated thousand TBE cases, most resulting in hospitalization, in Sweden from 2018 to 2022. To prevent additional TBE cases in Sweden, enhanced efforts to increase TBE vaccine uptake and compliance to the TBE vaccination schedule are needed. |
| format | Article |
| id | doaj-art-256e267ef0f742458bd4879c639e9018 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-256e267ef0f742458bd4879c639e90182025-01-26T12:27:56ZengNature PortfolioScientific Reports2045-23222025-01-011511810.1038/s41598-025-86968-yTick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022Andreas Palmborg0Frederick J. Angulo1Pingping Zhang2Andreas Pilz3James Stark4Jennifer C. Moïsi5Luis Jodar6Medical and Scientific Affairs, PfizerGlobal Vaccines and Anti-infectives Medical Affairs, PfizerEvidence Generation Statistics, PfizerGlobal Vaccines and Anti-infectives Medical Affairs, PfizerGlobal Vaccines and Anti-infectives Medical AffairsGlobal Vaccines and Anti-infectives Medical Affairs, PfizerGlobal Vaccines and Anti-infectives Medical Affairs, PfizerAbstract Tick-borne encephalitis (TBE) is an increasing health threat in Sweden and elsewhere in Europe. TBE vaccination is commonly recommended in Sweden, but limited data are available on uptake, effectiveness, and impact of TBE vaccination. General population surveys conducted in 2019–2022 were used to estimated TBE vaccine uptake. TBE vaccine effectiveness (VE) was estimated using the screening method utilizing the surveys and public health TBE surveillance data, which predominately includes hospitalized TBE cases, from 2018 to 2022. Impact of TBE vaccination was calculated based on disease incidence and observed VE. In 2018–2022, 2,015 TBE cases were reported in Sweden; 82.8% (1,564/1,890) of cases with known TBE vaccination history were unvaccinated. Among persons surveyed from the general population with known vaccination history, 52.0% (11,562/22,247) were unvaccinated. Three dose VE against TBE was 89.0% (95% confidence interval 84.3–92.4). When stratified by age group, VE was 86.0% (55.7–95.6) in 1–15 years-of-age and 93.8% (87.5–96.9) in 16–49 years-of-age. In a conservative estimate, despite suboptimal compliance with TBE vaccination recommendations, vaccination averted an estimated thousand TBE cases, most resulting in hospitalization, in Sweden from 2018 to 2022. To prevent additional TBE cases in Sweden, enhanced efforts to increase TBE vaccine uptake and compliance to the TBE vaccination schedule are needed.https://doi.org/10.1038/s41598-025-86968-yVector-borne diseaseEpidemiologySurveillancePreventionPublic healthVaccine |
| spellingShingle | Andreas Palmborg Frederick J. Angulo Pingping Zhang Andreas Pilz James Stark Jennifer C. Moïsi Luis Jodar Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022 Scientific Reports Vector-borne disease Epidemiology Surveillance Prevention Public health Vaccine |
| title | Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022 |
| title_full | Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022 |
| title_fullStr | Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022 |
| title_full_unstemmed | Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022 |
| title_short | Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022 |
| title_sort | tick borne encephalitis vaccine uptake effectiveness and impact in sweden from 2018 to 2022 |
| topic | Vector-borne disease Epidemiology Surveillance Prevention Public health Vaccine |
| url | https://doi.org/10.1038/s41598-025-86968-y |
| work_keys_str_mv | AT andreaspalmborg tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 AT frederickjangulo tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 AT pingpingzhang tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 AT andreaspilz tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 AT jamesstark tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 AT jennifercmoisi tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 AT luisjodar tickborneencephalitisvaccineuptakeeffectivenessandimpactinswedenfrom2018to2022 |